Bristol-Myers Squibb Company

Equities

BMY

US1101221083

Pharmaceuticals

Market Closed - Nyse 04:00:02 2024-03-04 pm EST 5-day change 1st Jan Change
50.92 USD +0.06% Intraday chart for Bristol-Myers Squibb Company +0.79% -0.76%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
U.S. Medicare negotiations for drug prices underway, Biden says RE
Bristol-Myers Squibb Keeps Quarterly Dividend at $0.60 a Share, Payable May 1 to Shareholders of Record April 5 MT
Bristol-Myers Squibb Company Declares Quarterly Dividend on Common Stock, Payable on May 1, 2024 CI
US judge upholds Medicare drug price negotiation program RE
Bristol-Myers Squibb Says Extension Study of Zeposia Shows Long-term Efficacy in Multiple Sclerosis Patients MT
Bristol Myers: positive results in multiple sclerosis CF
Global markets live: Chevron, Expedia, Standard Chartered, Broadcom, Meta Platforms... Our Logo
What could go wrong? Our Logo
Bristol Myers CEO says India to have largest R&D presence outside US by 2025 RE
Bristol-Myers Squibb Completes RayzeBio Acquisition MT
Bristol Myers: acquisition of RayzeBio finalized CF
Bristol-Myers Squibb Company completed the acquisition of RayzeBio, Inc.. CI
Bristol-Myers Says European Panel Issues Positive Opinion for Reblozyl to Treat Transfusion-Dependent Anemia MT
Bristol Myers Squibb Says RayzeBio Shareholders Overwhelmingly Accept $4.1 Billion Buyout Offer MT
Bristol Myers: positive CHMP opinion in anemia CF
Bristol Myers Wraps RayzeBio Tender Offer with 86% of Shares DJ
Bristol Myers: successful takeover bid for RayzeBio CF
Bristol Myers Gets CHMP Backing for Expanded Reblozyl Use DJ
Bristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl® (luspatercept) for Treatment of Adults with Transfusion-Dependent Anemia due to Low- to Intermediate-Risk Myelodysplastic Syndromes CI
Immunocore Collaborates With Bristol Myers Squibb in Advanced Cutaneous Melanoma Trial MT
Immunocore Holdings plc Announces Supply Agreement with Bristol Myers Squibb to Provide nivolumab CI
Aurora Cannabis Names Simona King CFO; Completes Share Consolidation MT
Bristol Myers: priority review in colorectal cancer CF
Bristol Myers Gets Priority FDA Review of Expanded Krazati Use DJ
Bristol Myers Squibb Announces U.S. Food and Drug Administration Accepts for Priority Review the Supplemental New Drug Application for KRAZATI in Combination with Cetuximab for the Treatment of Patients with Previously Treated KRASG12C-Mutated Locally Advanced or Metastatic Colorectal Cancer CI
  1. Stock
  2. Equities
  3. Stock Bristol-Myers Squibb Company - Nyse
  4. News Bristol-Myers Squibb Company
  5. Bristol Myers Squibb Insider Bought Shares Worth $150,049, According to a Recent SEC Filing
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.
SIGN UP NOW